AUPHAurinia Pharmaceuticals Inc.
What is the market doing?
No clear lean: nothing decisive, though in an uptrend.
In an uptrend, above its rising 50- and 200-day averages. Price is +7% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Moderately shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How AUPH is trading
Aurinia Pharmaceuticals Inc. is +28% over the past year while the S&P 500 is +18%: 9.8 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +7.1%
vs 200-day average · close to trend
- RSI (14)
- 51
RSI (14) · neutral
- Below its 52-week high
- 11%
Below its 52-week high
Details›
- Last close2026-10-09
- $16.65
- 1 monthS&P 500 +2.7%
- +3.4%
- 1 yearS&P 500 +18%
- +28%
- 5 yearsS&P 500 +88%
- −23%
- vs 50-day average$16.06
- +3.7%
- 52-week high
- $18.62
- 52-week low
- $11.05
- Annualised volatility
- 43%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- $12M
| Year | Return |
|---|---|
| 2026 (year to date) | +4.4% |
| 2025 | +78% |
| 2024 | −0.11% |
| 2023 | +108% |
| 2022 | −81% |
| 2021 | +65% |
| 2020 | −32% |
| 2019 | +197% |
| 2018 | +51% |
| 2017 | +116% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 4 of 10 | +11% |
| Feb | 10 | 3 of 10 | −5.2% |
| Mar | 10 | 5 of 10 | +9.2% |
| Apr | 10 | 7 of 10 | +0.63% |
| May | 10 | 5 of 10 | −0.29% |
| Jun | 10 | 6 of 10 | +1.3% |
| Jul | 11 | 6 of 11 | +0.76% |
| Aug | 11 | 7 of 11 | −0.01% |
| Sep | 11 | 6 of 11 | +7.9% |
| Oct | 11 | 6 of 11 | +4.2% |
| Nov | 10 | 6 of 10 | +4.5% |
| Dec | 10 | 5 of 10 | +12% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.